News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
713,865 Results
Type
Article (42325)
Company Profile (436)
Press Release (671104)
Multimedia
Podcasts (77)
Webinars (13)
Section
Business (208740)
Career Advice (2022)
Deals (36006)
Drug Delivery (104)
Drug Development (83578)
Employer Resources (173)
FDA (16427)
Job Trends (15095)
News (352790)
Policy (33077)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2645)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50953)
ALS (93)
Alzheimer's disease (1425)
Antibody-drug conjugate (ADC) (136)
Approvals (16416)
Artificial intelligence (263)
Autoimmune disease (25)
Automation (16)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (330)
Bladder cancer (70)
Brain cancer (26)
Breast cancer (280)
Cancer (2212)
Cardiovascular disease (182)
Career advice (1689)
Career pathing (30)
CAR-T (152)
Cell therapy (429)
Cervical cancer (19)
Clinical research (67708)
Collaboration (859)
Compensation (527)
Complete response letters (24)
COVID-19 (2644)
CRISPR (42)
C-suite (243)
Cystic fibrosis (105)
Data (2128)
Decentralized trials (2)
Denatured (28)
Depression (49)
Diabetes (268)
Diagnostics (6417)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (106)
Drug shortages (26)
Duchenne muscular dystrophy (99)
Earnings (87680)
Editorial (39)
Employer branding (21)
Employer resources (147)
Events (115638)
Executive appointments (725)
FDA (17660)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (780)
Gene editing (109)
Generative AI (21)
Gene therapy (314)
GLP-1 (742)
Government (4498)
Grass and pollen (4)
Guidances (52)
Healthcare (19144)
Huntington's disease (24)
IgA nephropathy (27)
Immunology and inflammation (126)
Indications (29)
Infectious disease (2788)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (94)
Interviews (311)
IPO (16781)
IRA (43)
Job creations (3701)
Job search strategy (1435)
Kidney cancer (10)
Labor market (38)
Layoffs (491)
Leadership (17)
Legal (7985)
Liver cancer (73)
Lung cancer (318)
Lymphoma (149)
Machine learning (6)
Management (58)
Manufacturing (305)
MASH (68)
Medical device (13512)
Medtech (13517)
Mergers & acquisitions (19747)
Metabolic disorders (705)
Multiple sclerosis (79)
NASH (19)
Neurodegenerative disease (98)
Neuropsychiatric disorders (33)
Neuroscience (1979)
NextGen: Class of 2025 (6757)
Non-profit (4547)
Northern California (2624)
Now hiring (39)
Obesity (381)
Opinion (223)
Ovarian cancer (75)
Pain (85)
Pancreatic cancer (82)
Parkinson's disease (153)
Partnered (21)
Patents (230)
Patient recruitment (106)
Peanut (47)
People (58640)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21267)
Phase II (29877)
Phase III (22096)
Pipeline (1164)
Policy (141)
Postmarket research (2601)
Preclinical (9080)
Press Release (67)
Prostate cancer (103)
Psychedelics (37)
Radiopharmaceuticals (262)
Rare diseases (398)
Real estate (6014)
Recruiting (66)
Regulatory (22699)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (42)
Schizophrenia (74)
Series A (138)
Series B (89)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2267)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3761)
State (2)
Stomach cancer (14)
Supply chain (68)
Tariffs (32)
The Weekly (47)
United States (23032)
Vaccines (693)
Venture capitalists (43)
Weight loss (252)
Women's health (37)
Worklife (16)
Date
Today (166)
Last 7 days (620)
Last 30 days (2514)
Last 365 days (33865)
2025 (10086)
2024 (36303)
2023 (41016)
2022 (52277)
2021 (56763)
2020 (54921)
2019 (47421)
2018 (35699)
2017 (33029)
2016 (32349)
2015 (38400)
2014 (32187)
2013 (27112)
2012 (29222)
2011 (29867)
2010 (27995)
Location
Africa (737)
Alabama (57)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (39219)
Australia (6528)
California (6057)
Canada (1980)
China (514)
Colorado (267)
Connecticut (278)
Delaware (141)
Europe (85719)
Florida (881)
Georgia (203)
Idaho (57)
Illinois (537)
India (25)
Indiana (309)
Iowa (11)
Japan (159)
Kansas (105)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (889)
Massachusetts (4598)
Michigan (218)
Minnesota (390)
Mississippi (2)
Missouri (82)
Montana (29)
Nebraska (25)
Nevada (60)
New Hampshire (66)
New Jersey (1713)
New Mexico (30)
New York (1710)
North Carolina (1017)
North Dakota (7)
Northern California (2624)
Ohio (202)
Oklahoma (14)
Oregon (38)
Pennsylvania (1349)
Puerto Rico (11)
Rhode Island (33)
South America (1111)
South Carolina (22)
South Dakota (1)
Southern California (2267)
Tennessee (101)
Texas (899)
Utah (179)
Virginia (145)
Washington D.C. (63)
Washington State (565)
West Virginia (3)
Wisconsin (53)
713,865 Results for "curie therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Curis to Present at Upcoming Healthcare Conference in April 2025
April 3, 2025
·
1 min read
Press Releases
Curis Provides Fourth Quarter 2024 Business Update
April 1, 2025
·
14 min read
Business
Curie.Bio Adds $380M Series A Fund to Move Biotech Startups to Clinic
The biotech incubator said Wednesday the majority of the fund will be for clinical proof-of-concept studies, bringing the total funds raised by Curie.Bio to nearly $1 billion.
June 26, 2024
·
1 min read
·
Kate Goodwin
Genetown
Curie.Bio Raises $380M Pro Rata Series A Fund To Support Portfolio Companies Through Clinical Trials
We’re excited to announce today that we have closed $380 million for our latest fund, bringing the total funds raised by Curie.Bio to nearly $1 billion.
June 26, 2024
·
4 min read
Genetown
Curis to Present at Upcoming Healthcare Conferences in April
Curis, Inc. today announced that James Dentzer , President and Chief Executive Officer of Curis, will participate at the 23rd Annual Needham Virtual Healthcare Conference being held on April 8 - 11, 2024.
April 4, 2024
·
1 min read
Press Releases
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
March 31, 2025
·
1 min read
Genetown
Curis to Present Updated Data from the TakeAim Leukemia Study
Curis, Inc. announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET.
May 10, 2024
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Genetown
Curis Announces Additional Data from TakeAim Leukemia Study
Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, announced updated data from the ongoing TakeAim Leukemia study in relapsed/refractory AML to be presented at the ASCO and EHA conferences.
May 14, 2024
·
9 min read
Business
Curis Provides First Quarter 2024 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.
May 7, 2024
·
11 min read
1 of 71,387
Next
